FOXP3 and Its Cofactors as Targets of Immunotherapies

被引:15
作者
Nagai, Yasuhiro [1 ]
Lam, Lian [1 ]
Greene, Mark I. [1 ]
Zhang, Hongtao [1 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
Treg; Forkhead box P3 (FOXP3); Post-translational modification; Autoimmune; Cancer; REGULATORY T-CELL; TRANSCRIPTION FACTOR FOXP3; CUTTING EDGE; TGF-BETA; C-REL; PROTEIN; INHIBITION; PROMOTES; STABILITY; COMPLEX;
D O I
10.1016/j.eng.2019.01.001
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
Forkhead box P3 (FOXP3) is a "master regulator" of regulatory T cells (Tregs), which are a subset of T cells that can suppress the antigen-specific immune reaction and that play important roles in host tolerance and immune homeostasis. It is well known that FOXP3 forms complexes with several proteins and can be regulated by various post-translational modifications (PTMs) such as acetylation, phosphorylation, ubiquitination, and methylation. As a consequence, the PTMs change the stability of FOXP3 and its capability to regulate gene expression, and eventually affect Treg activity. Although FOXP3 per se is not an ideal drug target, deacetylases, acetyltransferases, kinases, and other enzymes that regulate the PTMs of FOXP3 are potential targets to modulate FOXP3 and Treg activity. However, FOXP3 is not the only substrate for most of these enzymes; thus, unwanted "on target/off FOXP3" side effects must be considered when inhibitors to these enzymes are used. In this review, we summarize recent progress in the study of FOXP3 cofactors and PTM proteins, and potential clinical applications in autoimmunity and cancer immunity. (C) 2019 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 95 条
[1]   Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway [J].
Abu-Eid, Rasha ;
Samara, Raed N. ;
Ozbun, Laurent ;
Abdalla, Maher Y. ;
Berzofsky, Jay A. ;
Friedman, Kevin M. ;
Mkrtichyan, Mikayel ;
Khleif, Samir N. .
CANCER IMMUNOLOGY RESEARCH, 2014, 2 (11) :1080-1089
[2]   From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation [J].
Bacchetta, Rosa ;
Barzaghi, Federica ;
Roncarolo, Maria-Grazia .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2018, 1417 (01) :5-22
[3]   Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity [J].
Barzaghi, Federica ;
Passerini, Laura ;
Bacchetta, Rosa .
FRONTIERS IN IMMUNOLOGY, 2012, 3
[4]   Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin [J].
Basu, Samik ;
Golovina, Tatiana ;
Mikheeva, Tatiana ;
June, Carl H. ;
Riley, James L. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (09) :5794-5798
[5]   Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms [J].
Beier, Ulf H. ;
Wang, Liqing ;
Han, Rongxiang ;
Akimova, Tatiana ;
Liu, Yujie ;
Hancock, Wayne W. .
SCIENCE SIGNALING, 2012, 5 (229)
[6]   Sirtuin-1 Targeting Promotes Foxp3+ T-Regulatory Cell Function and Prolongs Allograft Survival [J].
Beier, Ulf H. ;
Wang, Liqing ;
Bhatti, Tricia R. ;
Liu, Yujie ;
Han, Rongxiang ;
Ge, Guanghui ;
Hancock, Wayne W. .
MOLECULAR AND CELLULAR BIOLOGY, 2011, 31 (05) :1022-1029
[7]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[8]   Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactions [J].
Bin Dhuban, Khalid ;
d'Hennezel, Eva ;
Nagai, Yasuhiro ;
Xiao, Yan ;
Shao, Steven ;
Istomine, Roman ;
Alvarez, Fernando ;
Ben-Shoshan, Moshe ;
Ochs, Hans ;
Mazer, Bruce ;
Li, Bin ;
Sekine, Chiyoko ;
Berezov, Alan ;
Hancock, Wayne ;
Torgerson, Troy R. ;
Greene, Mark I. ;
Piccirillo, Ciriaco A. .
SCIENCE IMMUNOLOGY, 2017, 2 (12)
[9]   Epigenetics in cancer: Fundamentals and Beyond [J].
Biswas, Subhankar ;
Rao, C. Mallikarjuna .
PHARMACOLOGY & THERAPEUTICS, 2017, 173 :118-134
[10]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784